These data indicate that DS-M1 has a high potency as an antitumor drug with the potential to provide survival advantage in acute leukemia patients with MLL-r and NPM1-mu. Currently, a Phase 1/2 clinical study of DS-M1 is planned in AML and ALL patients with MLL-r or NPM1-mu.

almost 4 years ago

Clinical • IO biomarker

NPM1 (Nucleophosmin 1) • CD38 (CD38 Molecule) • CD34 (CD34 molecule) • HOXA9 (Homeobox A9) • CD14 (CD14 Molecule) • ITGAM (Integrin, alpha M) • MEIS1 (Meis Homeobox 1)

NPM1 mutation • MLL rearrangement • MLL rearrangement • CD14 expression • MLL fusion

DS-M1